BioNexus Gene Lab

BioNexus Gene Lab Stock-Based Compensation

The Stock-Based Compensation (SBC) of BioNexus Gene Lab (BGLC) as of Oct 29, 2026 is 794,770.00 USD. In the previous year, Stock-Based Compensation (SBC) was 141,000.00 USD — a change of 463.67% (higher).

Stock-Based Compensation

794,770.00USD

YoY

463.67%

Last updated:

Stock-Based Compensation (SBC) of BioNexus Gene Lab is 2025 794,770.00 USD. Stock-Based Compensation (SBC) of BioNexus Gene Lab was 2024 141,000.00 USD. It decreases by 463.67% higher compared to the previous year.

The BioNexus Gene Lab Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2022
0.00 USD
Jan 1, 2023
511,740.00 USD
Jan 1, 2024
141,000.00 USD
Jan 1, 2025
794,770.00 USD
The BioNexus Gene Lab Stock-Based Compensation history
YEARStock-Based CompensationYoY
794,770.00USD+463.67%
141,000.00USD-72.45%
511,740.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNexus Gene Lab Stock analysis

What does BioNexus Gene Lab do? BioNexus Gene Lab Corp. develops and markets non-invasive blood tests for early disease detection, analyzing RNA changes to assess risks for over 11 diseases. The company’s subsidiary, Bionexus Gene Lab Sdn. Bdh., supports these operations. Products are sold to healthcare providers and diagnostic centers seeking advanced, non-invasive testing solutions. The firm targets medical professionals and institutions focused on personalized health management through functional genomics applications. The company generates revenue through the sale of its RNA-based blood tests, which are marketed as tools for early disease risk assessment. Healthcare institutions and diagnostic service providers purchase these tests to enhance their diagnostic capabilities. The focus on non-invasive methods aligns with growing demand for patient-friendly diagnostic technologies in the molecular diagnostics sector. BioNexus Gene Lab Corp. operates with a small team of 5 full-time employees, emphasizing efficiency in product development and marketing. The subsidiary Bionexus Gene Lab Sdn. Bdh. facilitates local operations, though specific market segments are not detailed beyond healthcare providers and diagnostic centers. Revenue streams are derived solely from test sales, with no mention of additional services or partnerships. BioNexus Gene Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNexus Gene Lab stock

Stock-Based Compensation (SBC) of BioNexus Gene Lab is 794,770.00 USD in 2025.

Stock-Based Compensation (SBC) of BioNexus Gene Lab changed from 141,000.00 USD to 794,770.00 USD, representing a 463.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s BioNexus Gene Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioNexus Gene Lab

All Key Metrics — BioNexus Gene Lab